Download Unicorn Signals App

Powered By EquityPandit
 Signals, Powered By  EquityPandit
Latest News

Sun Pharma, Almirall have entered into an agreement for psoriasis novel biologic

Sun Pharmaceutical Industries Ltd. signage is displayed outside the company's corporate office in the Andheri suburb of Mumbai, India, on Monday, April 7, 2014. Sun Pharmaceutical, India's largest drugmaker by market value, agreed to buy Ranbaxy Laboratories Ltd. for $3.2 billion in stock, the biggest purchase by an Indian company in two years. Photographer: Amit Madheshiya/Bloomberg via Getty Images

Sun Pharmaceutical and Almirall which is a Spanish firm have entered into a licencing agreement for development and commercialisation of tildrakizumab which is used to treat psoriasis in Europe.

The companies have said in a joint statement that “Under terms of the licence agreement, Almirall will pay Sun Pharma an initial upfront payment of USD 50 million.”

It further said that Sun Pharma will be eligible of receiving development and regulatory milestone payments and additionally sales milestone payments and royalties on net sales, the terms of that are confidential.

Read EquityPandit’s Technical Analysis on Nifty Pharma 

Get Daily Prediction & Stocks Tips On Your Mobile